SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mamelok, R D
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mamelok, R D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Effects of mycophenolate mofetil on transplant coronary artery disease and survival following cardiac transplantation

R D Mamelok

Mamelok Consulting, Palo Alto, CA, USA, mamelok{at}pacbell.net

Cardiac allograft vasculopathy is a leading cause of death in patients undergoing cardiac transplantation. This disease of coronary arteries in characterized by diffuse intimal thickening and narrowing of the vessel lumen. Mycophenolate mofetil (MMF) is a prodrug that is efficiently metabolized to mycophenolic acid (MPA) and which is an effective suppressor of T and B lymphocyte proliferation. MMF also leads to inhibition of lymphocyte adhesion and migration, smooth muscle proliferation. these mechanisms lead to decreased cellular rejection and in a controlled clinical trial MMF, compared to azathioprine, has been demonstrated to improve patient survival, in part by diminishing deaths due to cardiovascular causes. MMF has also been demonstrated to reduce titres of anti-vimentin antibodies, which have been shown to be a marker for increased risk of coronary vascular disease. Data from intravascular ultrasound, angiography and autopsies suggest that MMF by diminish the development of cardiac allograft vasculopathy, which may explain the improvement in survival observed after MMF therapy.

Key Words: acute rejection • post-transplant coronary artery disease • atherosclerosis • cardiac transplantation • mycophenolate mofetil

Lupus, Vol. 15, No. 11 suppl, 18-22 (2006)
DOI: 10.1177/0961203306071673
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement